Fig. 2: High AVIL expression is correlated with worse clinical prognosis of glioma patients.
From: A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma
a Clinical analysis using the REMBRANDT dataset. A three-class model, stratified by AVIL RNA expression in 343 glioma cases. Higher expression of AVIL correlates with worse overall patient survival (p = 1 × 10−4, two-sided log-rank test). b A two-class model stratified by AVIL protein expression in the 14 GBM samples. The high AVIL group has worse overall survival than the low AVIL group (p = 5 × 10−4, two-sided log-rank test). c Clinical analysis using TCGA lower-grade glioma dataset. A two-class model stratified by AVIL RNA expression in 286 samples that have RNA-sequencing data. The high AVIL group has a much shorter overall survival than the low AVIL group (p = 1 × 10−5, two-sided log-rank test). The median survival for the high AVIL group is 23.1 months, versus 75.1 months for the low AVIL group.
